Epiodyne
Donald Gehlert, Ph.D. has worked in various roles in the scientific and healthcare fields since 1987. Donald began as a Unit Chief at NINDS in 1987 and then moved to Eli Lilly and Company in 1989, where they served as a Research Fellow and Group Leader until 2015. Since then, they have worked as a Consultant for Mindmed (2019), Spruce Biosciences (2017), EMERpharma Ltd (2015), Cerecor Inc. (2015), and Anagin Inc. (2015). In addition, they have held the role of Chief Scientific Officer at Epiodyne (2017) and Adjunct Associate Professor in the Departments of Psychiatry and Neuroscience at Indiana University School of Medicine (1990). Donald is currently the Owner of Matrix Pharma Consulting, LLC (2015).
Donald Gehlert, Ph.D. began their educational journey in 1973 when they attended Walter P. Chrysler High School. Donald then went on to pursue a B.S. in Pharmacy at Purdue University from 1976 to 1981. Finally, they earned their Ph.D. in Pharmacology from the University of Utah School of Medicine between 1981 and 1985.
This person is not in any teams
This person is not in any offices
Epiodyne
Epiodyne was founded to develop breakthrough small molecule medicines based upon novel insights into GPCR receptor pharmacology that were uncovered by leading researchers at UCSF, Stanford and Duke. They are using quantitative pharmacological and behavioral techniques to translate their insights into novel medicines for patients with opioid use disorder (OUD). They are backed by a syndicate of experienced biotech VCs and located in the Bay Area.